<DOC>
	<DOCNO>NCT00560794</DOCNO>
	<brief_summary>The purpose study determine whether bispecific T-cell engager ( BiTE® ) Blinatumomab ( MT103 ) effective treatment ALL patient minimal residual disease .</brief_summary>
	<brief_title>Phase II Study BiTE® Blinatumomab ( MT103 ) Patients With Minimal Residual Disease B-precursor Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>The presence leukemia cell cytological detection limit ( 5 % leukemic cell ) define minimal residual disease ( MRD ) . If MRD detectable ( &lt; 10^-4 = le 1 leukemia cell per 10^4 bone marrow cell ) complete molecular remission reach . In last year series retrospective study show MRD adult ALL independent prognostic factor already demonstrate childhood leukemia . Diagnostic tool MRD polymerase chain reaction ( PCR ) and/or flow cytometry . PCR analysis detect fusion transcript bcr/abl individual clonal rearrangement immunoglobulin ( IgH ) and/or T-cell receptor gene ( TCR ) . About 25 % patient MRD define rearrangement comprise high-risk group 94 % relapse rate within 3 year . In general patient MRD , eligible allogenic stem cell transplantation , curative treatment available . This account MRD define Philadelphia chromosome translocation well MRD define rearrangement . The current study set address question treat MRD positive ALL bispecific anti-cluster differentiation ( CD ) 19 x anti-CD3 antibody derivative blinatumomab ( MT103 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Bprecursor ALL patient complete hematological remission molecular failure molecular relapse start time consolidation I frontline therapy within German Multicenter Study Group Adult Acute Lymphoblastic Leukemia ( GMALL ) standard time outside GMALL standard . Patients must molecular marker evaluation minimal residual disease either Breakpoint cluster region/gene human chromosome # 9 ( Bcr/abl ) detection level individual rearrangement immunoglobulin Tcell receptor ( TCR ) gene measure assay sensitivity minimum 10^4 : At least one individual marker quantitative level ≥ 10^4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 Ability understand willingness sign write informed consent Signed date write informed consent available Current extra medullar involvement History current relevant central nervous system ( CNS ) pathology ( except migraine/headache and/or previous infiltration cerebrospinal fluid ( CSF ) ALL ) Current infiltration cerebrospinal fluid ALL History current autoimmune disease Autologous stem cell transplantation within 6 week prior study entry Any prior allogeneic stem cell transplantation Cancer chemotherapy within 4 week prior study treatment ( except intrathecal prophylaxis and/or low dose maintenance therapy vinca alkaloid , mercaptopurine , methotrexate , steroid ) Radiotherapy within 4 week prior study treatment Therapy monoclonal antibody ( Rituximab , MabCampath ) within 6 week prior study treatment Known hypersensitivity immunoglobulins component study drug formulation Presence human antimurine antibody ( HAMA ) Abnormal bone marrow , renal hepatic function Indication hypercoagulative state History malignancy ALL within 5 year prior study entry , exception basal cell carcinoma skin cervix carcinoma situ Active severe infection , concurrent disease medical condition deem interfere conduct study judge investigator Known infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus ( HbsAg positive ) hepatitis C virus ( antiHCV positive ) Pregnant nursing woman Women childbearing potential willing use effective form contraception participation study least 3 month thereafter male patient willing ensure effective contraception participation study least three month thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Minimal Residual Disease</keyword>
	<keyword>adult ALL</keyword>
	<keyword>immunotherapeutic treatment</keyword>
	<keyword>anti-CD19 bispecific antibody derivative</keyword>
	<keyword>Blinatumomab</keyword>
	<keyword>MT103</keyword>
</DOC>